Use of the GnRH Agonist Leuprolide Acetate (Lupron(Registered Trademark)) to Preserve Ovarian Function in Women Undergoing Chemotherapy.

Trial Profile

Use of the GnRH Agonist Leuprolide Acetate (Lupron(Registered Trademark)) to Preserve Ovarian Function in Women Undergoing Chemotherapy.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Cetrorelix (Primary)
  • Indications Infertility
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Mar 2012 Official Title amended as reported by ClinicalTrials.gov.
    • 20 Mar 2012 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 23 Jul 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top